BJP Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
QUICK SEARCH:   [advanced]


     

Journal of Mental Science (1961) 107: 250-257. doi: 10.1192/bjp.107.447.250
© 1961 The Royal College of Psychiatrists
This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stanley, W. J.
Right arrow Articles by Walton, D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Stanley, W. J.
Right arrow Articles by Walton, D.

Trifluoperazine ("Stelazine") A Controlled Clinical Trial in Chronic Schizophrenia

W. J. Stanley, M.B. Ch.B., D.P.M., Senior Psychiatric Registrar

Winwick Hospital

D. Walton, B.A., Dip.Psych.(Lond.), Principal Clinical Psychologist, Winwick Hospital

ABSTRACT

A controlled trial of trifluoperazine (Stelazine) in chronic schizophrenia is reported. Analysis of the results indicates that this substance is of value in the symptomatic treatment of this condition, and that the less severely affected patients appear to benefit most from its use. Neither the age of the patient nor the length of time in hospital seem to influence the results of treatment. It was not found possible to show that one symptom or group of symptoms responded better than another, but further investigation with larger numbers of patients might yield results in this respect, and would be of value in leading to more precise indications for the use of this drug.

Side-effects, mainly in the form of extra-pyramidal dysfunction, were fairly common but tended to disappear on reduction of dosage; they were not considered to be a serious disadvantage of the drug, and should seldom necessitate discontinuation of treatment. The incidence of side-effects can be reduced by commencing with a small dose and then gradually increasing, and probably also by using twice daily rather than thrice daily administration.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 1961 The Royal College of Psychiatrists.